Initial Statement of Beneficial Ownership (3)
July 02 2020 - 7:18PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Kihara James |
2. Date of Event Requiring Statement (MM/DD/YYYY)
6/23/2020
|
3. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ACAD]
|
(Last)
(First)
(Middle)
C/O ACADIA PHARMACEUTICALS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Principal Accounting Officer / |
(Street)
SAN DIEGO, CA 92130
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (Right to Buy) | (1) | 4/6/2030 | Common Stock | 32302 | $41.71 | D | |
Restricted Stock Units | (2) | (2) | Common Stock | 5955 | (3) | D | |
Explanation of Responses: |
(1) | 25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
(2) | 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024. |
(3) | Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Kihara James C/O ACADIA PHARMACEUTICALS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO, CA 92130 |
|
| Principal Accounting Officer |
|
Signatures
|
/s/ James K. Kihara | | 7/2/2020 |
**Signature of Reporting Person | Date |
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024